| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020697966 |
| P356 | DOI | 10.2165/11599950-000000000-00000 |
| P698 | PubMed publication ID | 22435343 |
| P5875 | ResearchGate publication ID | 221902034 |
| P50 | author | Philippe Mabo | Q114428170 |
| P2093 | author name string | Juan Tamargo | |
| Alessandro Capucci | |||
| P2860 | cites work | Hypertonic sodium bicarbonate in an acute flecainide overdose | Q77190220 |
| Proarrhythmia | Q77535837 | ||
| Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity | Q79286425 | ||
| Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial | Q79831278 | ||
| Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome | Q93571413 | ||
| Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography | Q28166512 | ||
| Clinical course and outcome in class IC antiarrhythmic overdose | Q28243514 | ||
| Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 | ||
| Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia | Q32055132 | ||
| Efficacy of quinidine in high-risk patients with Brugada syndrome | Q33151791 | ||
| Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics | Q33155056 | ||
| Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment | Q33158584 | ||
| The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events | Q33160108 | ||
| Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey | Q33541615 | ||
| Issues in the use of generic antiarrhythmic drugs | Q34109855 | ||
| Antiarrhythmic agents: drug interactions of clinical significance | Q34122414 | ||
| Proarrhythmia | Q34172223 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation | Q34505579 | ||
| The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease | Q34512892 | ||
| The influence of urinary pH on flecainide excretion and its serum pharmacokinetics | Q34621131 | ||
| Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation | Q35057258 | ||
| Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials | Q35096843 | ||
| Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing | Q35589436 | ||
| Pharmacological cardioversion of atrial fibrillation: current management and treatment options | Q35962527 | ||
| Proarrhythmia in patients treated for atrial fibrillation or flutter | Q36212688 | ||
| Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man | Q36741131 | ||
| Paranoid psychosis and myoclonus: flecainide toxicity in renal failure | Q37122997 | ||
| Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects | Q37142440 | ||
| Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism | Q37321429 | ||
| Fetal arrhythmia: prenatal diagnosis and perinatal management | Q37596538 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | Q37611786 | ||
| Drug therapy. Flecainide | Q39734380 | ||
| Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy | Q39814750 | ||
| Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent | Q70333490 | ||
| Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome | Q70390804 | ||
| Oral digoxin pharmacokinetics during multiple-dose flecainide treatment | Q70576439 | ||
| Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed | Q70992150 | ||
| Extracardiac adverse effects of flecainide | Q71267296 | ||
| Electrophysiologic properties of flecainide acetate | Q71267301 | ||
| Interaction of flecainide with digoxin and propranolol | Q71267311 | ||
| Flecainide dose-response relations in stable ventricular arrhythmias | Q71267316 | ||
| Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram | Q71267319 | ||
| Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate | Q71691470 | ||
| Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia | Q71742056 | ||
| Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide | Q71821703 | ||
| Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone | Q72329234 | ||
| Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects | Q72346628 | ||
| Biotransformation and elimination of 14C-flecainide acetate in humans | Q72588317 | ||
| Response of an Abnormal Sinus Node to Intravenous Flecainide Acetate | Q72737178 | ||
| Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm | Q73128790 | ||
| A proposal for the clinical use of flecainide | Q40169636 | ||
| Metabolism of flecainide | Q40169641 | ||
| ECG findings in fatal flecainide intoxication. | Q40694123 | ||
| Newer antidepressants and the cytochrome P450 system | Q40976263 | ||
| Using the right drug: a treatment algorithm for regular supraventricular tachycardias | Q41471350 | ||
| Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. | Q41968501 | ||
| Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine | Q42208316 | ||
| Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart | Q42225717 | ||
| Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. | Q42275434 | ||
| Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group | Q42556865 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Flecainide toxicity | Q42965248 | ||
| Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study | Q43152056 | ||
| Altered pharmacokinetics of oral flecainide by cimetidine. | Q43240553 | ||
| Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias | Q43641442 | ||
| Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients | Q43826181 | ||
| Flecainide in the intrauterine treatment of fetal supraventricular tachycardia | Q43904385 | ||
| Amiodarone used in successful resuscitation after near-fatal flecainide overdose | Q43955542 | ||
| Meta-analysis of flecainide safety in patients with supraventricular arrhythmias | Q44110400 | ||
| Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients | Q44413384 | ||
| Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. | Q45002973 | ||
| Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach | Q45170339 | ||
| Oral flecainide pharmacokinetics in patients with impaired renal function | Q45180817 | ||
| Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. | Q46011482 | ||
| Pharmacokinetics of flecainide acetate in patients with severe renal impairment | Q46064281 | ||
| Flecainide-induced neuropathy | Q46632209 | ||
| Flecainide: safety and efficacy | Q46674363 | ||
| Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. | Q50545052 | ||
| Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. | Q52868280 | ||
| Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. | Q54118671 | ||
| Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. | Q54439949 | ||
| Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. | Q54446063 | ||
| Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. | Q54458024 | ||
| Effects of flecainide on ventricular function: clinical and experimental correlations. | Q54479320 | ||
| Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. | Q54527568 | ||
| Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols | Q57013753 | ||
| Influence of amiodarone on genetically determined drug metabolism in humans | Q57314137 | ||
| Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide | Q58819306 | ||
| Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension | Q58819310 | ||
| Flecainide: evidence of non-linear kinetics | Q58819313 | ||
| Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter | Q61965304 | ||
| Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes | Q68339880 | ||
| Flecainide excretion in human breast milk | Q68355620 | ||
| Late proarrhythmia and understanding the time of occurrence of proarrhythmia | Q68361332 | ||
| Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate | Q69211390 | ||
| Pharmacodynamics and side effects of flecainide acetate | Q69543967 | ||
| The effect of flecainide acetate, a new antiarrhythmic, on plasma digoxin levels | Q70017964 | ||
| Effect of flecainide on cardiac output | Q70058793 | ||
| Oral flecainide acetate for the treatment of ventricular arrhythmias | Q70162383 | ||
| Influence of left ventricular dysfunction on flecainide therapy | Q70316369 | ||
| Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function | Q70331568 | ||
| ??? | Q28341602 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 273-289 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Safety of flecainide | |
| P478 | volume | 35 |
| Q30653045 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures |
| Q45162471 | A Micropatterned Human Pluripotent Stem Cell-Based Ventricular Cardiac Anisotropic Sheet for Visualizing Drug-Induced Arrhythmogenicity |
| Q48272406 | An 89-year-old man presents with worsening heart failure. |
| Q38072091 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias |
| Q33643591 | Flecainide and elevated liver enzymes in α1-antitrypsin deficiency |
| Q36437641 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. |
| Q33625455 | Intermittent failure to capture: What is the mechanism? |
| Q35547234 | Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. |
| Q54954354 | Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia. |
| Q38072867 | Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up |
Search more.